Involvement of PI3K, GSK-3β and PPARγ in the antidepressant-like effect of folic acid in the forced swimming test in mice

Journal of Psychopharmacology

Volumn 26, Issue 5, 2012, Pages 714-723

  Budni, Josiane ^a   Lobato, Kelly R ^a   Binfaré, Ricardo W ^a   Freitas, Andiara E ^a   Costa, Ana Paula ^a   Martín De Saavedra, Maria Dolores ^b,c   Leal, Rodrigo B ^a   Lopez, Manuela G ^b,c   Rodrigues, Ana Lúcia S ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c INSTITUTO TEÓFILO HERNANDO   (Spain)

Author keywords

Antidepressant; folic acid; forced swimming test; GSK 3 ; PI3K; PPAR

Indexed keywords

FOLIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; FORCED SWIMMING TEST; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; FOLIC ACID; GLYCOGEN SYNTHASE KINASE 3; MALE; MICE; MOTOR ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASES; PPAR GAMMA; SWIMMING;

EID: 84856610955     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111424456     Document Type: Article

References (68)

1. Abou-Saleh MT, Coppen A. Folic acid and the treatment of depression. J Psychosom Res. 2006 ; 61: 285-287
2. Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry. 2002 ; 14: 33-38
3. Beaulieu JM, Gainetdinov RR, Caron MG. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol. 2009 ; 49: 327-347
4. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC, et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA. 2008 ; 105: 1333-1338
5. BeaulieuJM (2011) A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci doi: 10.1503/jpn.11001110.1503/jpn.110011. [Epub ahead of print]
6. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem. 2004 ; 89: 1313-1317
7. Bourin M, Masse F, Hascoët M. Evidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming test. J Psychiatry Neurosci. 2005 ; 30: 275-282
8. Brazil DK, Yang Z, Hemmings BA. Advances in protein kinase B signaling: AKTion on multiple fronts. Trends Biochem Sci. 2004 ; 29: 233-242
9. Brocardo PS, Budni J, Kaster MP, Santos ARS, Rodrigues ALS. Folic acid administration produces an antidepressant-like effect in mice: evidence for the involvement of the serotonergic and noradrenergic systems. Neuropharmacology. 2008a ; 54: 464-473
10. Brocardo PS, Budni J, Lobato KR, Kaster MP, Rodrigues ALS. Antidepressant-like effect of folic acid: Involvement of NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway. Eur J Pharmacol. 2008b ; 598: 37-42
11. Brocardo PS, Budni J, Lobato KR, Santos ARS, Rodrigues ALS. Evidence for the involvement of the opioid system in the antidepressant-like effect of folic acid in the mouse forced swimming test. Behav Brain Res. 2009 ; 200: 122-127
12. Brocardo PS, Budni J, Pavesi E, Franco JL, Uliano-Silva M, Trevisan R, et al. Folic acid administration prevents ouabain-induced hyperlocomotion and alterations in oxidative stress markers in the rat brain. Bipolar Disord. 2010 ; 12 (4). 414-424
13. Budni J, Gadotti VM, Kaster MP, Santos ARS, Rodrigues ALS. Role of different types of potassium channels in the antidepressant-like effect of agmatine in the mouse forced swimming test. Eur J Pharmacol. 2007 ; 575: 87-93
14. Budni J, Romero A, Molz S, Martín-de-Saavedra MD, Egea J, Del Barrio L, et al. Neurotoxicity induced by dexamethasone in the human neuroblastoma SH-SY5Y cell line can be prevented by folic acid. Neuroscience. 2011 ; 190: 346-353
15. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002 ; 296: 1655-1657
16. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem. 1999 ; 72: 1327-1330
17. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomized, placebo controlled trial. J Affect Disord. 2000 ; 60: 121-130
18. Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol. 2005 ; 19: 59-65
19. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995 ; 378: 785-789
20. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci. 2002 ; 23: 238-245
21. Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev. 2005 ; 29: 547-569
22. Dazzi L, Matzeu A, Biggio G. Role of ionotropic glutamate receptors in the regulation of hippocampal norepinephrine output in vivo. Brain Res. 2011 ; 1386: 41-49
23. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999 ; 20: 649-688
24. Dwivedi Y, Rizavi HS, Teppen T, Zhang H, Mondal A, Roberts RC, et al. Lower phosphoinositide 3-kinase (PI 3-kinase) activity and differential expression levels of selective catalytic and regulatory PI 3-kinase subunit isoforms in prefrontal cortex and hippocampus of suicide subjects. Neuropsychopharmacology. 2008 ; 33: 2324-2340
25. Eissa Ahmed AA, Al-Rasheed NM, Al-Rasheed NM. Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav Pharmacol. 2009 ; 20: 635-642
26. Ghasemi M, Raza M, Dehpour AR. NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. J Psychopharmacol. 2010 ; 24: 585-594
27. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990 ; 336: 392-395
28. Gould TD. Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications. Expert Opin Ther Targets. 2006 ; 10: 377-392
29. Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology. 2005 ; 30: 1223-1237
30. Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol. 2004a ; 7: 387-390
31. Gould TD, Picchini AM, Einat H, Manji HK. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets. 2006 ; 7: 1399-1409
32. Gould TD, Zarate CA, Manji HK. Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J Clin Psychiatry. 2004b ; 65: 10-21
33. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase in cellular signalling. Prog Neurobiol. 2001 ; 65: 391-426
34. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT -a major therapeutic target. Biochim Biophys Acta. 2004 ; 1697: 3-16
35. Heiss A, Ammer H, Eisinger DA. Delta-Opioid receptor-stimulated Akt signaling in neuroblastoma x glioma (NG108-15) hybrid cells involves receptor tyrosine kinase-mediated PI3K activation. Exp Cell Res. 2009 ; 315: 2115-2125
36. Hetman M, Cavanaugh JE, Kimelman D, Xia Z. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci. 2000 ; 20: 2567-2574
37. Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M. Peroxisome proliferator-activated receptor γ is expressed in hippocampal neurons and its activation prevents β-amyloid neurodegeneration: role of Wnt signaling. Exp Cell Res. 2005 ; 304: 91-104
38. Johnson M, Hanson GR, Gibb JW. Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog. Eur J Pharmacol. 1989 ; 165: 315-318
39. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry. 1999 ; 4: 117-128
40. Jope RS, Roh M. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets. 2006 ; 7: 1421-1434
41. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry. 2004 ; 55: 781-784
42. Kalinichev M, Dawson LA. Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. Int J Neuropsychopharmacol. 2011 ; 6: 1-17
43. Kaster MP, Budni J, Binfaré RW, Santos ARS, Rodrigues ALS. The inhibition of different types of potassium channels underlies the antidepressant-like effect of adenosine in the mouse forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry. 2007 ; 31: 690-696
44. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001 ; 17: 615-675
45. Kelly A, Lynch MA. Long-term potentiation in dentate gyrus of the rat is inhibited by the phosphoinositide 3-kinase inhibitor, wortmannin. Neuropharmacology. 2000 ; 39: 643-651
46. Kronenberg G, Colla M, Endres M. Folic acid, neurodegenerative and neuropsychiatric disease. Curr Mol Med. 2009 ; 9: 315-323
47. Leão RM, Von Gersdorff H. Noradrenaline increases high-frequency firing at the calyx of held synapse during development by inhibiting glutamate release. J Neurophysiol. 2002 ; 87: 2297-2306
48. Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Dis. 2002 ; 4: 137-144
49. Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology. 2004 ; 29: 1426-1431
50. López-Gil X, Artigas F, Adell A. Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action. Int J Neuropsychopharmacol. 2009 ; 12: 487-499
51. Masuko T, Suzuki I, Kizawa Y, Kusama-Eguchi K, Watanabe K, Kashiwagi K, et al. Monoamines directly inhibit N-methyl-D-aspartate receptors expressed in Xenopus oocytes in a voltage-dependent manner. Neurosci Lett. 2004 ; 371: 30-33
52. Olianas MC, Dedoni S, Onali P. Regulation of PI3K/Akt signaling by N-desmethylclozapine through activation of δ-opioid receptor. Eur J Pharmacol. 2011 ; 660: 341-350
53. Picchini AM, Manji HK, Gould TD. GSK-3 and neurotrophic signaling: novel targets underlying the pathophysiology and treatment of mood disorders?. Drug Discov Today Dis Mech. 2004 ; 1: 419-428
54. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977 ; 229: 327-336
55. Rasgon NL, Kenna HA, Williams KE, Powers B, Wroolie T, Schatzberg AF. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. ScientificWorldJournal. 2010 ; 10: 321-328
56. Redrobe JP, Bourin M. Evidence of the activity of lithium on 5-HT1B receptors in the mouse forced swimming test: comparison with carbamazepine and sodium valproate. Psychopharmacology (Berl). 1999 ; 141: 370-377
57. Rodrigues ALS, Rosa JM, Gadotti VM, Goulart EC, Santos MM, Silva AV, et al. Antidepressant-like and antinociceptive-like actions of 4-(4′- chlorophenyl)-6-(4″-methylphenyl)-2-hydrazinepyrimidine Mannich base in mice. Pharmacol Biochem Behav. 2005 ; 82: 156-162
58. Roh MS, Kang UG, Shin SY, Lee YH, Jung HY, Juhnn YS, et al. Biphasic changes in the Ser-9 phosphorylation of glycogen synthase kinase-3beta after electroconvulsive shock in the rat brain. Prog Neuropsychopharmacol Biol Psychiatry. 2003 ; 27: 1-5
59. Rosa AO, Lin J, Calixto JB, Santos ARS, Rodrigues ALS. Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res. 2003 ; 144: 87-93
60. Rosa AO, Kaster MP, Binfaré RW, Morales S, Martín-Aparicio E, Navarro-Rico ML, et al. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2008 ; 32: 1549-1556
61. Rowe MK, Wiest C, Chuang DM. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev. 2007 ; 31: 920-931
62. Sarris J, Schoendorfer N, Kavanagh DJ. Major depressive disorder and nutritional medicine: a review of monotherapies and adjuvant treatments. Nutr Rev. 2009 ; 67: 125-131
63. Segieth J, Pearce B, Fowler L, Whitton PS. Regulatory role of nitric oxide over hippocampal 5-HT release in vivo. Naunyn-Schmiedeberg's Arch Pharmacol. 2001 ; 363: 302-306
64. Seto SW, Lam TY, Or PM, Lee WY, Au AL, Poon CC, et al. Folic acid consumption reduces resistin level and restores blunted acetylcholine-induced aortic relaxation in obese/diabetic mice. J Nutr Biochem. 2010 ; 21: 872-880
65. Szabo C, Mitchell JA, Thiemermann C, Vane JR. Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol. 1993 ; 108: 786-792
66. Taylor MJ, Carney SM, Goodwin GM, Geddes JR. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol. 2004 ; 18: 251-256
67. Yang PC, Yang CH, Huang CC, Hsu KS. Phosphatidylinositol 3-kinase activation is required for stress protocol-induced modification of hippocampal synaptic plasticity. J Biol Chem. 2008 ; 283: 2631-2643
68. Yessoufou A, Wahli W. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly. 2010 ; 140: w13071